全髋关节置换术后口服氨甲环酸24小时与单次术前静脉剂量的随机对照试验
TRAC-24为前瞻性单中心开放标签平行组随机对照试验,纳入534例初次单侧择期全髋关节置换患者,比较术中1g静脉氨甲环酸加术后24小时口服方案、仅术中单次剂量及不用氨甲环酸三组。结果显示两干预组48小时间接计算失血量无显著差异,各组的死亡率或静脉血栓栓塞发生率也无差异。
要点
- 术后追加24小时口服氨甲环酸未能在单次1g静脉剂量基础上进一步减少失血量。
- 在体重指数正常患者中可能存在有临床意义的差异,值得进一步研究。
- 有血栓栓塞、心血管或脑血管疾病史的患者未见安全性问题。
核心结论
- 术后追加24小时口服氨甲环酸不能比单次1g静脉围手术期剂量进一步减少失血量。
- 在体重指数正常患者中可能存在有临床意义的差异,值得进一步研究。
- 有血栓栓塞、心血管或脑血管疾病史的患者未见安全性问题。
研究设计与样本
- TRAC-24为前瞻性、IV期、单中心、开放标签、平行组随机对照试验,纳入初次单侧择期全髋关节置换患者。
- 共随机534例,第1组233例,第2组235例,第3组66例,其中92例(17.2%)被认为高风险。
- 主要结局指标为48小时间接计算失血量。
主要发现
- 两干预组平均间接计算失血量无显著差异:第1组848.4 ml(SD 463.8),第2组843.7 ml(SD 478.7),平均差-4.7 ml(95%CI -82.9至92.3),p=0.916。
- 任何组间均未观察到死亡率或静脉血栓栓塞发生率的差异。
临床怎么用
- 全髋关节置换术中单次1g静脉氨甲环酸即可,术后追加24小时口服方案未显示额外减少失血。
- 对有血栓栓塞、心血管或脑血管疾病史的患者,使用氨甲环酸未观察到安全性问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: A typical pattern of blood loss associated with total hip arthroplasty (THA) is 200 ml intraoperatively and 1.3 l in the first 48 postoperative hours. Tranexamic acid (TXA) is most commonly given as a single preoperative dose only and is often withheld from patients with a history of thromboembolic disease as they are perceived to be "high-risk" with respect to postoperative venous thromboembolism (VTE). The TRanexamic ACid for 24 hours trial (TRAC-24) aimed to identify if an additional 24-hour postoperative TXA regime could further reduce blood loss beyond a once-only dose at the time of surgery, without excluding these high-risk patients. METHODS: TRAC-24 was a prospective, phase IV, single centre, open label, parallel group, randomized controlled trial (RCT) involving patients undergoing primary unilateral elective THA. The primary outcome measure was the indirect calculated blood loss (IBL) at 48 hours. The patients were randomized into three groups. Group 1 received 1 g intravenous (IV) TXA at the time of surgery and an additional oral regime for 24 hours postoperatively, group 2 only received the intraoperative dose, and group 3 did not receive any TXA. RESULTS: A total of 534 patients were randomized, with 233 in group 1, 235 in group 2, and 66 in group 3; 92 patients (17.2%) were considered high-risk. The mean IBL did not differ significantly between the two intervention groups (848.4 ml (SD 463.8) for group 1, and 843.7 ml (SD 478.7) for group 2; mean difference -4.7 ml (95% confidence interval -82.9 to 92.3); p = 0.916). No differences in mortality or incidence of VTE were observed between any group. CONCLUSION: The addition of oral TXA for 24 hours postoperatively does not reduce blood loss beyond that achieved with a single 1 g IV perioperative dose alone. There may be a clinically relevant difference in patients with a normal BMI, which warrants further investigation. Critically, there were no safety issues in patients with a history of thromboembolic, cardiovascular, or cerebrovascular disease. Cite this article: Bone Joint J 2021;103-B(7):1197-1205.
引用
- Magill P, Hill JC, Bryce L, et al. Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total hip arthroplasty: results of a randomized controlled trial (TRAC-24). Bone Joint J. 2021. PMID: 34192922. doi:10.1302/0301-620X.103B7.BJJ-2020-2309.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。